Combination therapies represent a promising frontier in cancer treatment, addressing the critical need to enhance efficacy ...
SAN FRANCISCO -- Progression-free survival (PFS) in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) more than doubled with the addition of the somatostatin analog (SSA) lanreotide (Somatuline ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
Near Okemah, Okla., rancher Buck Rich has been using combination treatment for several years under the guidance of his ...
Researchers at the UNC School of Medicine and the UNC Eshelman School of Pharmacy have made a breakthrough that could modernize treatment for glioblastoma. In a study published in Proceedings of the ...
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the ...
In patients with an aggressive form of breast cancer, treatment with the antibody-drug conjugate sacituzumab govitecan plus pembrolizumab resulted in durable responses with improved progression free ...
QPOP demonstrates high accuracy in predicting AML treatment responses, with 87.3% success in generating individualized drug sensitivity reports. QPOP revealed drug resistance mechanisms and predicted ...
Vir Biotechnology, Inc. (VIR) has already been able to initiate its late-stage ECLIPSE program, which is using the combination of monoclonal antibody tobevibart in combination with small interfering ...
Cancer treatment has made remarkable strides. New drugs and technologies have changed outcomes for many patients, turning some once-fatal diagnoses into manageable conditions. Yet despite these ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results